Samsung Biologics and Lilly Partner to Launch Korea Innovation Hub

Event summary

  • Samsung Biologics and Lilly will establish a Gateway Labs site in Korea, supporting up to 30 biotech companies.
  • The 125,000 sq. ft. facility, part of Samsung Biologics' Bio Campus II, is expected to open in July 2027.
  • Lilly Gateway Labs will provide scientific engagement and operational support to resident companies.
  • The initiative aims to strengthen Korea's biotechnology ecosystem and attract global innovation activity.

The big picture

This collaboration underscores the growing trend of CDMOs partnering with pharmaceutical giants to foster early-stage biotech innovation. By leveraging Lilly's global network and Samsung Biologics' manufacturing capabilities, the initiative aims to bridge the gap between scientific discovery and commercialization, potentially reshaping Korea's biotech landscape. The success of this model could set a precedent for similar partnerships in emerging biotech hubs.

What we're watching

Ecosystem Growth
How the Gateway Labs site will impact Korea's position as a hub for early-stage life science research.
Funding Momentum
Whether resident companies can replicate the $3 billion collective funding raised by previous Gateway Labs participants.
Strategic Alignment
The pace at which Samsung Biologics and Lilly can integrate their expertise to accelerate drug discovery and development.